BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 1157063)

  • 1. [Complex effect of mercurascan on ischaemia-induced myocardial injury].
    Málek P; Kolc J; Vrána M; Kucerová V; Mrhová O; Vránová Z
    Cas Lek Cesk; 1975 Jun; 114(25):753-7. PubMed ID: 1157063
    [No Abstract]   [Full Text] [Related]  

  • 2. Studies on the therapeutic use of mercurascan (MSC). Part 1: Distribution of mercurascan in the body in experimental and clinical myocardial ischaemia.
    Málek P; Vavrejn B; Kolc J; Ratuský J
    Int J Clin Pharmacol; 1974 Dec; 10(4):266-72. PubMed ID: 4443131
    [No Abstract]   [Full Text] [Related]  

  • 3. Studies on the therapeutic use of mercurascan (MSC). Part 2: Antiarrhythmogenic and haemodynamic effect of MSC in experimental myocardial ischaemia.
    Málek P; Vrána M; Kolc J; Netusil M; Blazek Z
    Int J Clin Pharmacol; 1974 Dec; 10(4):273-82. PubMed ID: 4140846
    [No Abstract]   [Full Text] [Related]  

  • 4. Studies on the therapeutic use of Mercurascar. Part IV: The effect of Mercurascan on some metabolic changes in experimental myocardial ischaemia. Section II: Enzymes.
    Mrhová O; Kolc J; Málek P
    Int J Clin Pharmacol Biopharm; 1975 Jan; 11(1):52-7. PubMed ID: 125244
    [No Abstract]   [Full Text] [Related]  

  • 5. Studies on the therapeutic use of Mercurascar. Part III. Influence of Mercurascan on some metabolic changes in experimental myocardial ischaemia in dogs. Section I: Energetic and ionic metabolism.
    Kucerová V; Kolc J; Málek P
    Int J Clin Pharmacol Biopharm; 1975 Jan; 11(1):40-51. PubMed ID: 1150362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective effect of Mercurascan after coronary artery ligation in the dog.
    Málek I; Kolc J; Mrhová O; Urbanová D; Málek P
    Eur J Cardiol; 1980; 12(1):55-62. PubMed ID: 7439234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The effect of mercurascan on some of the metabolic parameters of myocardial ischaemia in the early phases after heart transplantation in the dog (author's transl)].
    Brodan V; Táborský J; Hejnal J; Málek P; Andĕl M
    Cas Lek Cesk; 1979 Apr; 118(14):438-40. PubMed ID: 378375
    [No Abstract]   [Full Text] [Related]  

  • 8. [Velocity of the selective accumulation of Mercurascan 203 in injured muscle and in the ischemic myocardium].
    Málek P; Vavrejn B; Ratuský J; Kronrád L; Kolc J
    Experientia; 1967 Aug; 23(8):649-51. PubMed ID: 6051694
    [No Abstract]   [Full Text] [Related]  

  • 9. Mercurascan test in ischaemia of the heart muscle caused by permanent ligature of the coronary artery.
    Málek P; Kolc J; Vavrejn B; Ratuský J; Kronrád L
    Rev Czech Med; 1971; 17(1):11-5. PubMed ID: 5576153
    [No Abstract]   [Full Text] [Related]  

  • 10. Beta-blockade in experimental myocardial ischaemia: metabolic and electrocardiographic effects.
    Thomas M; Norris R; Opie L; Shulman G; Owen P
    Br Heart J; 1971 Jul; 33(4):609. PubMed ID: 4397629
    [No Abstract]   [Full Text] [Related]  

  • 11. Metabolism of Mercurascan-203Hg by rats and dogs.
    Dreyfuss J; Ross JJ; Shaw JM
    J Nucl Biol Med; 1973; 17(2):43-50. PubMed ID: 4754433
    [No Abstract]   [Full Text] [Related]  

  • 12. Studies on isoprenaline-induced myocardial lesions. 1. Quantitative evaluation by mercurascan uptake.
    Faltová E; Mráz M; Kronrád L; Protivová L; Sedivý J
    Basic Res Cardiol; 1977; 72(5):454-63. PubMed ID: 588200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Use of a new diagnostic and antiarrhythmic agent, mercurascan, in experimental myocardial infarct].
    Malek P; Vavreĭn B; Kolts I; Vrana M; Ratuskiĭ I
    Eksp Khir Anesteziol; 1975; (6):3-11. PubMed ID: 1234540
    [No Abstract]   [Full Text] [Related]  

  • 14. Ultrastructural and biochemical alterations induced by propranolol treatment in experimental myocardial ischaemia.
    Laky D; Constantinescu S; Filipescu G; Constantinescu NM; Ratea E; Hălălău F
    Morphol Embryol (Bucur); 1981; 27(3):249-53. PubMed ID: 6460936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experimental studies in transient myocardial ischaemia.
    Laky D; Constantinescu S; Filipescu G; Constantinescu NM; Ratea E; Halalau F
    Acta Morphol Acad Sci Hung; 1982; 30(3-4):299-307. PubMed ID: 6301225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Possibilities of protecting the ischemic focus in the myocardium].
    Málek I; Kolc J; Mrhová O; Urbanová D; Ratuský J
    Cas Lek Cesk; 1985 Aug; 124(32):1011-4. PubMed ID: 4028084
    [No Abstract]   [Full Text] [Related]  

  • 17. The effects of carbochromen on myocardial blood flow and metabolic heat production before and after acute coronary ligation.
    Grayson J; Irvine M; Parratt JR
    Br J Pharmacol; 1969 Oct; 37(2):523P-524P. PubMed ID: 5348445
    [No Abstract]   [Full Text] [Related]  

  • 18. Nifedipine for angina and acute myocardial ischaemia.
    Hugenholtz PG; Verdouw PD; de Jong JW; Serruys PW
    Postgrad Med J; 1983; 59 Suppl 2():40-58. PubMed ID: 6351043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Electrical instability of the heart in acute local myocardial ischaemia: pathogenesis and experimental prevention.
    Vrána M; Fejfar Z; Vránová Z; Hess L; Blazek Z
    Cor Vasa; 1986; 28(2):114-22. PubMed ID: 2426034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conservative management of exomphalos major.
    Merwaha DC; Gupta RL; Gupta RR; Mullick RN
    Indian J Pediatr; 1973 Apr; 40(303):151-3. PubMed ID: 4758009
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.